Sawai Pharmaceutical Announces More Structured Proposal For Kyorin Merger, Eyeing Consolidation For Biosimilars In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Generics firm Sawai Pharmaceutical announced late Dec. 2 that it has proposed a merger with Kyorin Pharmaceutical to capitalize on alliance strength - a recent common trend in Japan - and create a biosimilar presence in the country, which has launched a nationwide campaign to increase generic usage. But Kyorin has spurned Sawai's advances before, and it is unclear whether the newest proposal will be sweet enough to progress